News
Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results